Abstract
The targeted therapies available to treat metastatic kidney cancer include vascular endothelial growth factor (VEGF) inhibitors, bevacizumab, sorafenib, sunitinib, pazopanib, and the mTor inhibitors temsirolimus and everolimus. These agents have significantly improved patient outcomes but are associated with toxicities. The most common toxicities seen with the VEGF inhibitors are hypertension, fatigue, and hand- foot syndrome. The mTor inhibitors exhibit a different toxicity profile which includes hyperglycemia and hypertriglyceridemia. Recognition and understanding the mechanism of the toxicities is crucial for optimal patient management.
Keywords: Advanced renal cell carcinoma, targeted drugs, toxicity, mechanism, Hypertension, Proteinuria, Cardiotoxicity, Gastrointestinal Toxicities, Arterial Thrombosis, Hepatic Toxicities, Pulmonary Toxicity
Current Clinical Pharmacology
Title: Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Volume: 6 Issue: 3
Author(s): Priti Patel and Sandy Srinivas
Affiliation:
Keywords: Advanced renal cell carcinoma, targeted drugs, toxicity, mechanism, Hypertension, Proteinuria, Cardiotoxicity, Gastrointestinal Toxicities, Arterial Thrombosis, Hepatic Toxicities, Pulmonary Toxicity
Abstract: The targeted therapies available to treat metastatic kidney cancer include vascular endothelial growth factor (VEGF) inhibitors, bevacizumab, sorafenib, sunitinib, pazopanib, and the mTor inhibitors temsirolimus and everolimus. These agents have significantly improved patient outcomes but are associated with toxicities. The most common toxicities seen with the VEGF inhibitors are hypertension, fatigue, and hand- foot syndrome. The mTor inhibitors exhibit a different toxicity profile which includes hyperglycemia and hypertriglyceridemia. Recognition and understanding the mechanism of the toxicities is crucial for optimal patient management.
Export Options
About this article
Cite this article as:
Patel Priti and Srinivas Sandy, Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma, Current Clinical Pharmacology 2011; 6 (3) . https://dx.doi.org/10.2174/157488411797189442
DOI https://dx.doi.org/10.2174/157488411797189442 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Polyphenols Regulate Endothelial Functions and Reduce the Risk of Cardiovascular Disease
Current Pharmaceutical Design ACE2; an ACE up the Sleeve?
Current Enzyme Inhibition From the Stretcher to the Pharmacys Shelf: Drug Leads from Medically Important Brazilian Venomous Arachnid Species
Inflammation & Allergy - Drug Targets (Discontinued) Subject Index to Volume 2
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Bioorganic Compounds Produced by the Fungus Monascus and their Use in Health Sciences and Medicine
Mini-Reviews in Organic Chemistry Angiotensin-TGF-β1 Crosstalk in Human Idiopathic Pulmonary Fibrosis:Autocrine Mechanisms in Myofibroblasts and Macrophages
Current Pharmaceutical Design Biocatalysis: Synthesis of Chiral Intermediates for Pharmaceuticals
Current Organic Chemistry Individual Differences in the Neurobiology of Social Stress: Implications for Depression-Cardiovascular Disease Comorbidity
Current Neuropharmacology Cardiovascular Toxicity of Cyclooxygenase Inhibitors and Promising Natur a l Substitutes
Current Pharmaceutical Design Impact of Ocular Compatible Lipoids and Castor Oil in Fabrication of Brimonidine Tartrate Nanoemulsions by 3<sup>3</sup> Full Factorial Design
Recent Patents on Inflammation & Allergy Drug Discovery Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal A Dietary Approach for Treating Dyslipidemia and Hyperglycemia
Current Nutrition & Food Science Editorial [Hot Topic Cardiovascular and Metabolic Diseases: from Mechanisms to Novel Therapeutical Implications Guest Editors: Attila Borbély and Pawel Petkow Dimitrow]
Current Pharmaceutical Biotechnology Antihypertensive Drugs that Act on Renin-Angiotensin System with Emphasis in AT1 Antagonists
Mini-Reviews in Medicinal Chemistry The Renin Inhibitor Aliskiren as Novel Treatment for Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Users Perception of Risk and Benefits of Mood Modifying Drugs
Current Clinical Pharmacology Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research Factors Associated with Primary Hypertension in Pediatric Patients: An Up-to-Date
Current Pediatric Reviews Glutathione Modulation and Oxidative Stress in Human Liver Slices
Current Drug Discovery Technologies